Search Results | Blood | American Society of Hematology

1-20 of 128

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Tommaso Matteuzzi, Daniele Dall'Olio, Eric Sträng, Alessandra Merlotti, Javier Martinez Elicegui, Axel Benner, Maral Saadati, Julia Krzykalla, Caroline A. Heckman, Ana Heredia Casanoves, Jurjen Versluis, María Abáigar, Alberto Hernandez-Sanchez, Laura Jamilis, Peter JM Valk, Klaus H. Metzeler, Rosa Ayala, Joaquin Martinez Lopez, Herve Dombret, Pau Montesinos, Jorge Sierra, Claude Preudomme, Frederick Damm, Ken I Mills, Raúl Azibeiro Melchor, Jiří Mayer, Christian Thiede, Maria Teresa Voso, Sergio Amadori, Guillermo Sanz, Frederico Calado, Konstanze Döhner, Verena I Gaidzik, Michael Heuser, Torsten Haferlach, Marta Sobas, Amin T. Turki, Dirk Reinhardt, Rubén Villoria Medina, Michel van Speybroeck, Renate Schulze-Rath, Jesús M Hernández Rivas, Brian J.P Huntly, Hartmut Döhner, Gert J. Ossenkoppele, Castellani Gastone, Lars Bullinger

Blood (2021) 138 (Supplement 1): 3438.

DOI: https://doi.org/10.1182/blood-2021-152215

Published: 2021

Journal Articles

Germline and Somatic Variants Co-Ocurrence Profile in Early Onset Adult Myelodysplastic Syndromes without a Preexisting Disorder

Blood (2021) 138 (Supplement 1): 2595.

DOI: https://doi.org/10.1182/blood-2021-152128

Published: 2021

Journal Articles

Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry

Blood (2021) 138 (Supplement 1): 2610.

DOI: https://doi.org/10.1182/blood-2021-152678

Published: 2021

Journal Articles

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

María Diez-Campelo, Luis E. Benlloch, Emma Sasse, David Wormser, Leyla Hernandez Donoso, Silvia Colicino, Teresa Bernal, Antonieta Molero Yordi, Mar Tormo, Montserrat Arnan Sangerman, Guillermo Sanz, Marina Díaz-Beyá, María Teresa Cedena Romero, Andres Jerez, Brayan Merchán, David Valcárcel

Blood (2021) 138 (Supplement 1): 2605.

DOI: https://doi.org/10.1182/blood-2021-146019

Published: 2021

Journal Articles

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)

Blood (2021) 138 (Supplement 1): 2344.

DOI: https://doi.org/10.1182/blood-2021-147769

Published: 2021

Journal Articles

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Blood (2021) 138 (Supplement 1): 4669.

DOI: https://doi.org/10.1182/blood-2021-145626

Published: 2021

Journal Articles

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset

Blood (2021) 138 (Supplement 1): 4671.

DOI: https://doi.org/10.1182/blood-2021-150322

Published: 2021

Journal Articles

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 4041.

DOI: https://doi.org/10.1182/blood-2021-149521

Published: 2021

Journal Articles

Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance

Blood (2021) 138 (Supplement 1): 5031.

DOI: https://doi.org/10.1182/blood-2021-145002

Published: 2021

Journal Articles

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

Blood (2021) 138 (Supplement 1): 608.

DOI: https://doi.org/10.1182/blood-2021-150766

Published: 2021

Journal Articles

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study

Blood (2021) 138 (16): 1429–1440.

DOI: https://doi.org/10.1182/blood.2021011719

Published: 2021

Includes: Supplemental data

Journal Articles

Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction

Blood (2018) 132 (Supplement 1): 4339.

DOI: https://doi.org/10.1182/blood-2018-99-116045

Published: 2018

Journal Articles

Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death

Blood (2018) 132 (Supplement 1): 4385.

DOI: https://doi.org/10.1182/blood-2018-99-115928

Published: 2018

Journal Articles

Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome

Blood (2018) 132 (Supplement 1): 4363.

DOI: https://doi.org/10.1182/blood-2018-99-110210

Published: 2018

Journal Articles

Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study

Luca Vago, MD PhD, Cristina Toffalori, Müberra Ahci, Vinzenz Lange, PhD, Kathrin Lang, Sonia Todaro, Francesca Lorentino, Karin Stempelmann, Andreas Heinold, Friedrich Stoelzel, Miguel Waterhouse, Rainer Claus, Ketevan Gendzekhadze, Masahiro Onozawa, Raynier Devillier, Ruoping Tang, Maayan Ulman, Mi Kwon, Ivana Gojo, MD, Loredana Ruggeri, Annalisa Imovilli, Luca Facchini, Dejan Lazarevic, Maria Teresa Lupo Stanghellini, Jacopo Peccatori, Nina Kristin Steckel, Peter A. Horn, Alessandra Picardi, Sara Manetta, Alessandro Busca, Jose Luis Pinana, Jaime Sanz, Carolina Martínez-Laperche, Stefan O. Ciurea, Leo Luznik, MD, Andrea Velardi, William Arcese, Guillermo Sanz, Massimo Pini, Benedetto Bruno, Guido Kobbe, Monzr Al Malki, MD, Takanori Teshima, Nicolaus Kroeger, Jürgen Finke, MD, Arnon Nagler, MD, Didier Blaise, Mohamad Mohty, MD PhD, Martin Bornhäuser, Dietrich W. Beelen, Alexander H. Schmidt, Fabio Ciceri, MD, Katharina Fleischhauer

Blood (2018) 132 (Supplement 1): 818.

DOI: https://doi.org/10.1182/blood-2018-99-112142

Published: 2018

Journal Articles

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) — Preliminary Blinded Analysis of the European Sintra-REV Trial

Blood (2018) 132 (Supplement 1): 468.

DOI: https://doi.org/10.1182/blood-2018-99-119430

Published: 2018

Journal Articles

MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination

Blood (2018) 132 (Supplement 1): 4357.

DOI: https://doi.org/10.1182/blood-2018-99-111838

Published: 2018

Journal Articles

Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation

Jaap Jan Boelens, MD PhD, Coco de Koning, Mitchell E. Horwitz, MD, Guillermo Sanz, Madan Jagasia, MD MS, John E. Wagner, MD, Patrick J. Stiff, MD, Rabi Hanna, MD, Daniela Cilloni, MD PhD, Stefan Nierkens, PhD

Blood (2018) 132 (Supplement 1): 2123.

DOI: https://doi.org/10.1182/blood-2018-99-116700

Published: 2018

Journal Articles

Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization

Blood (2018) 132 (Supplement 1): 3048.

DOI: https://doi.org/10.1182/blood-2018-99-111883

Published: 2018

Journal Articles

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Andrea Kuendgen, MD, Meritxell Nomdedeu, Heinz Tuechler, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, Alan F. List, MD, Mario Cazzola, Amy E. DeZern, MD, Gail J. Roboz, MD, David P. Steensma, MD, Arjan A. Van de Loosdrecht, MD PhD, Hartmut Döhner, MD, Xavier Calvo, MD, Sabine Blum, Arturo Pereira, MD PhD, Peter Valent, Dolors Costa, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, Carme Pedro, MD, Michael Lübbert, Itziar Oiartzabal, Javier Grau, Maria Díez-Campelo, María Teresa Cedena, Sigrid Machherndl-Spandl, MD, Maria López-Pavía, Claudia D. Baldus, MD, Montserra Martinez-de-Sola, Reinhard Stauder, MD MSc, Brayan Merchan, Christina Ganster, Thomas Schroeder, Barbara Hildebrandt, Jordi Esteve, MD PhD, Benet Nomdedeu, Francesc Cobo, Francesc Sole, PhD, Rainer Haas, MD, Ulrich Germing, MD, Peter L Greenberg, MD, Detlef Haase, MD PhD, Guillermo Sanz

Blood (2018) 132 (Supplement 1): 3103.

DOI: https://doi.org/10.1182/blood-2018-99-118215

Published: 2018

2 3 4 5

NARROW

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Germline and Somatic Variants Co-Ocurrence Profile in Early Onset Adult Myelodysplastic Syndromes without a Preexisting Disorder

Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study

Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction

Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death

Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome

Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) — Preliminary Blinded Analysis of the European Sintra-REV Trial

MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination

Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation

Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only